{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:33:32Z","timestamp":1790642012245,"version":"4.1.0"},"reference-count":148,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Pharmacology"],"published-print":{"date-parts":[[2023,11,2]]},"DOI":"10.1080\/17512433.2023.2277882","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T11:27:13Z","timestamp":1699356433000},"page":"1125-1139","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":9,"title":["Novel pharmaceuticals for the management of retinal vein occlusion and linked disorders"],"prefix":"10.1080","volume":"16","author":[{"given":"Matthew","family":"Driban","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Kedia","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Arora","sequence":"additional","affiliation":[{"name":"Bahamas Vision Center and Princess Margaret Hospital, Nassau, New Providence, Bahamas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Chhablani","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,11,7]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2016.111"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2018.04.005"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e3182870c15"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.0352"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10030405"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2017.07.015"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(83)34530-9"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1980.01020040452011"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/724780"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000455278"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-022-02007-4"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.22608\/APO.2017163442"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2415-14-119"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007325.pub3"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2019.07.23"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5185128"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S4033"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004170100344"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00164677"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113457"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/438412"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.89.5.2462"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.84.2.154"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31821801de"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008158"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.2174\/1573399811666150615151324"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.234"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/594615"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.02.022"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2012.09.026"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2010.02.021"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.08.038"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.09.035"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2014.07.027"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2019.12.019"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH09-09-0626"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.2450\/2022.0276-21"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2021.100964"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2007.01144.x"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-008-0830-7"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S203212"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/APO.0000000000000286"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200110000-00002"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.956083"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-022-02246-5"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-022-00488-w"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-022-02177-1"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000003626"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.04.031"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-022-02287-w"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.5053"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.5403"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01713-3"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169424"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100302"},{"key":"e_1_3_4_59_1","unstructured":"New Phase III data show Genentech\u2019s Vabysmo Rapidly improved vision and reduced retinal fluid in people with retinal vein occlusion (RVO) [Internet]. Genentech Inc.; 2023. Available from: https:\/\/www.gene.com\/media\/press-releases\/14983\/2023-02-09\/new-phase-iii-data-show-genentechs-vabys"},{"key":"e_1_3_4_60_1","unstructured":"FDA accepts application for Genentech\u2019s vabysmo for the treatment of retinal vein occlusion (RVO) [Internet]; 2023 May 8. Available from: https:\/\/www.gene.com\/media\/press-releases\/14991\/2023-05-08\/fda-accepts-application-for-genentechs-v"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1177\/25158414211027708"},{"issue":"7","key":"e_1_3_4_62_1","first-page":"4286","article-title":"Updated results of Phase 1b study of KSI-301, an anti-VEGF antibody biopolymer conjugate with Extended durability, in wAMD, DME, and RVO","volume":"61","author":"Patel SS","year":"2020","unstructured":"Patel SS, Janer D, Miller B, et al. Updated results of Phase 1b study of KSI-301, an anti-VEGF antibody biopolymer conjugate with Extended durability, in wAMD, DME, and RVO. Invest Ophthalmol Visual Sci. 2020;61(7):4286\u20134286.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15051484"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2018.03.001"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-9872"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2020.08.007"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2018.03.008"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S351853"},{"issue":"13","key":"e_1_3_4_69_1","first-page":"S243","article-title":"Microinjection via the suprachoroidal space: a review of a novel mode of administration","volume":"28","author":"Ciulla T","year":"2022","unstructured":"Ciulla T, Yeh S. Microinjection via the suprachoroidal space: a review of a novel mode of administration. Am J Manag Care. 2022 Nov;28(13 Suppl):S243\u2013s252.","journal-title":"Am J Manag Care"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2021.1867532"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oret.2017.07.013"},{"key":"e_1_3_4_72_1","unstructured":"Clearside biomedical announces SAPPHIRE Phase 3 study of combination therapy in retinal vein occlusion did not meet its primary endpoint: Clearside Biomedical; 2018 [cited 2023]. Available from: https:\/\/ir.clearsidebio.com\/news-releases\/news-release-details\/clearside-biomedical-announces-sapphire-phase-3-study"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01766-w"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.01.006"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-023-02808-5"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.1998.168"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004170050235"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2008.0087"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.03.023"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.3109\/02713683.2012.705412"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2013\/6473.3766"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.iae.0000237584.56552.1c"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S170562"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1159\/000342160"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000003632"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.18-25084"},{"issue":"9","key":"e_1_3_4_87_1","first-page":"5673","article-title":"AR-1105 dexamethasone Extended release and pharmacokinetics in the non-human primate","volume":"59","author":"Tully J","year":"2018","unstructured":"Tully J, Williams S, Melton D, et al. AR-1105 dexamethasone Extended release and pharmacokinetics in the non-human primate. Invest Ophthalmol Visual Sci. 2018;59(9):5673\u20135673.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1177\/0300060518816884"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.4155\/tde-2019-0051"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S403259"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1177\/2515841418820755"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6678364"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2008.02.029"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2004.046607"},{"issue":"2","key":"e_1_3_4_95_1","first-page":"64","article-title":"Ocular effects of niacin: a review of the literature","volume":"4","author":"Domanico D","year":"2015","unstructured":"Domanico D, Verboschi F, Altimari S, et al. Ocular effects of niacin: a review of the literature. Med Hypothesis Discov Innov Ophthalmol. 2015 Summer;4(2):64\u201371.","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-017-3606-0"},{"issue":"1","key":"e_1_3_4_97_1","first-page":"36","article-title":"Nicotinic Acid Treatment for Retinal Vein Occlusion","volume":"2","author":"M A","year":"2014","unstructured":"M A, Mn M, S Z-G, et al. Nicotinic Acid Treatment for Retinal Vein Occlusion. J Patient Saf. 2014;2(1):36\u201343.","journal-title":"J Patient Saf"},{"issue":"14","key":"e_1_3_4_98_1","first-page":"5192","article-title":"High dose oral niacin as a treatment for retinal vein occlusions","volume":"53","author":"Paulus YM","year":"2012","unstructured":"Paulus YM, Gaynon MW, Leath JD, et al. High dose oral niacin as a treatment for retinal vein occlusions. Invest Ophthalmol Visual Sci. 2012;53(14):5192\u20135192.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2016.1028"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12139"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2013.05.018"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2009.288"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14821-z"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M409009200"},{"issue":"13","key":"e_1_3_4_107_1","first-page":"3831","article-title":"Effect of human Annexin A5 Eye drops on corneal epithelial wound healing in rabbits","volume":"44","author":"Kondo S","year":"2003","unstructured":"Kondo S, Watanabe M, Mizuno K, et al. Effect of human Annexin A5 Eye drops on corneal epithelial wound healing in rabbits. Invest Ophthalmol Visual Sci. 2003;44(13):3831\u20133831.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19041218"},{"issue":"8","key":"e_1_3_4_109_1","first-page":"3233","article-title":"ANXV (a human recombinant Annexin A5) is well-tolerated and safe in Phase 1 first in human clinical trial and is currently in Phase 2 in retinal vein occlusion","volume":"64","author":"Frostegaard A","year":"2023","unstructured":"Frostegaard A, Suchdev S, Frostegaard J, et al. ANXV (a human recombinant Annexin A5) is well-tolerated and safe in Phase 1 first in human clinical trial and is currently in Phase 2 in retinal vein occlusion. Invest Ophthalmol Visual Sci. 2023;64(8):3233\u20133233.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_110_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.11-8833"},{"key":"e_1_3_4_111_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.14-15415"},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e32834f94cb"},{"key":"e_1_3_4_114_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.07-1527"},{"issue":"5","key":"e_1_3_4_115_1","first-page":"4990","article-title":"Celecoxib attenuates retinal angiogenesis in a mouse model of oxygen-induced retinopathy","volume":"8","author":"Liu N","year":"2015","unstructured":"Liu N, Chen L, Cai N. Celecoxib attenuates retinal angiogenesis in a mouse model of oxygen-induced retinopathy. Int J Clin Exp Pathol. 2015;8(5):4990\u20134998.","journal-title":"Int J Clin Exp Pathol"},{"key":"e_1_3_4_116_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425241003663236"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.22462\/07.08.2018.6"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.15441\/ceem.17.271"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0202154"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S224192"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcab328"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.28920\/dhm50.4.431-436"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-013-0261-4"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.2.553.553"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04251.x"},{"key":"e_1_3_4_128_1","unstructured":"Girmens J-F Prevention of retinal non-perfusion in central retinal vein occlusion by hydroxycarbamide treatment. (PNPRO_HC). ClinicalTrialsgov identifier: NCT02957760. 2017."},{"key":"e_1_3_4_129_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15098"},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0698-11.2011"},{"issue":"8","key":"e_1_3_4_131_1","first-page":"1537","article-title":"Caspase-9 inhibitor eyedrops reduce edema and protect retinal function following central retinal vein occlusion","volume":"58","author":"Avrutsky M","year":"2017","unstructured":"Avrutsky M, Jean YY, White AJ, et al. Caspase-9 inhibitor eyedrops reduce edema and protect retinal function following central retinal vein occlusion. Invest Ophthalmol Visual Sci. 2017;58(8):1537\u20131537.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16902-5"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-05387-3"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1209527"},{"key":"e_1_3_4_135_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199550050-00007"},{"key":"e_1_3_4_136_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2019.1604001"},{"key":"e_1_3_4_137_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.iae.0000244265.75771.71"},{"key":"e_1_3_4_138_1","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_1450_22"},{"key":"e_1_3_4_139_1","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2018.0125"},{"key":"e_1_3_4_140_1","doi-asserted-by":"publisher","DOI":"10.5301\/ejo.5000591"},{"key":"e_1_3_4_141_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2019.1687729"},{"key":"e_1_3_4_142_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-022-00424-x"},{"key":"e_1_3_4_143_1","doi-asserted-by":"publisher","DOI":"10.3109\/08916930903510963"},{"key":"e_1_3_4_144_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.6.437"},{"key":"e_1_3_4_145_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2415-13-63"},{"key":"e_1_3_4_146_1","doi-asserted-by":"publisher","DOI":"10.18502\/jovr.v15i4.7785"},{"key":"e_1_3_4_147_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2011.3"},{"key":"e_1_3_4_148_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i28.4602"},{"issue":"11","key":"e_1_3_4_149_1","first-page":"735","article-title":"Interferon-induced central retinal vein thrombosis","volume":"22","author":"Nazir L","year":"2012","unstructured":"Nazir L, Husain A, Haroon W, et al. Interferon-induced central retinal vein thrombosis. J Coll Physicians Surg Pak. 2012 Nov;22(11):735\u2013736.","journal-title":"J Coll Physicians Surg Pak"},{"key":"e_1_3_4_150_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-032128"},{"key":"e_1_3_4_151_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-0770-y"},{"key":"e_1_3_4_152_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.biomac.2c00383"},{"key":"e_1_3_4_153_1","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202204994"},{"key":"e_1_3_4_154_1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9091203"},{"issue":"8","key":"e_1_3_4_155_1","first-page":"9729","article-title":"The therapeutic effect of Healaflow in glaucoma surgery","volume":"13","author":"Wu L","year":"2021","unstructured":"Wu L, Liu J, Chang X, et al. The therapeutic effect of Healaflow in glaucoma surgery. Am J Transl Res. 2021;13(8):9729\u20139735.","journal-title":"Am J Transl Res"},{"key":"e_1_3_4_156_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.07.031"}],"container-title":["Expert Review of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17512433.2023.2277882","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T15:28:47Z","timestamp":1727278127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17512433.2023.2277882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":148,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,2]]}},"alternative-id":["10.1080\/17512433.2023.2277882"],"URL":"https:\/\/doi.org\/10.1080\/17512433.2023.2277882","relation":{},"ISSN":["1751-2433","1751-2441"],"issn-type":[{"value":"1751-2433","type":"print"},{"value":"1751-2441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-08-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}